RxDoctor Payments Data

Andrew Porges, MD

Rheumatology · New Hyde Park, NYNPI 1295771087

Payments from drug & device makers

$157,843in general payments, 2019–2025

Across 89 payments — averaging $1773.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$117K
  • UCB SA$18K
  • AbbVie$18K
  • GSK$2K
  • Amgen$2K
  • Sanofi US Services Inc.$525
  • plus $177 from 5 others
$2,965in research payments, 2019–2025

Across 3 payments — averaging $988.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$3K

What the payments were for

  • Food & beverage$339100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$157,843 in reported general payments places this provider in the 85th percentile of 541 rheumatology providers in New York.

See all rheumatology providers in New York

Medicare billing

Part B allowed, 2024
$311,186
Medicare patients
1,142
Services billed
8,597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xeljanz XrTofacitinib Citrate92$791,347
Enbrel SureclickEtanercept53$570,115
RinvoqUpadacitinib32$388,904
Humira(Cf) PenAdalimumab22$331,810
StelaraUstekinumab12$330,061
SimponiGolimumab12$132,030
XeljanzTofacitinib Citrate17$123,986
BenlystaBelimumab12$121,528
Cosentyx Sensoready (2 Pens)Secukinumab13$98,690
Sildenafil Citrate14$14,678
Hydroxychloroquine Sulfate374$14,484
Febuxostat40$11,727
RasuvoMethotrexate/Pf16$11,453
Colchicine94$10,866
MethotrexateMethotrexate Sodium322$9,659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Simponi$119$462,09024 claims
AbbVieRinvoq$17,716$388,90432 claims
PfizerXeljanz$117,363$123,98617 claims
GSKBenlysta$2,000$121,52812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 541 rheumatology providers in New York.

Other rheumatology in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →